After launching on its maiden voyage in April, Seaport Therapeutics and its crew of Karuna veterans have loaded up with $225 million in series B funds to support the journey to key clinical milestones ...
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new drug. BMS’ first-in-class ...
The FDA has approved Karuna/Bristol Myers Squibb’s KarXT (Cobenfy) — an oral dual M1/M4 muscarinic acetylcholine receptor (mAChR) agonist — for schizophrenia. The fixed-dose combination of xanomeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback